Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma

Nature Biotechnology

Volumn 30, Issue 4, 2012, Pages 337-343

  Pulido, Jose ^a   Kottke, Timothy ^a   Thompson, Jill ^a   Galivo, Feorillo ^a   Wongthida, Phonphimon ^b   Diaz, Rosa Maria ^a   Rommelfanger, Diana ^a   Ilett, Elizabeth ^a,c   Pease, Larry ^d   Pandha, Hardev ^e   Harrington, Kevin ^f   Selby, Peter ^c   Melcher, Alan ^c   Vile, Richard ^a,c,d  

^a MAYO CLINIC   (United States)

^b NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY   (Thailand)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d MAYO GRADUATE SCHOOL   (United States)

^e UNIVERSITY OF SURREY   (United Kingdom)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-TUMORS; CDNA LIBRARIES; IN-VITRO; INTRAVENOUS INJECTIONS; LYMPHOID CELLS; MELANOMA CELLS; MELANOMA TUMORS; VESICULAR STOMATITIS VIRUS;

ANTIGENS; CELL CULTURE; CURING; DERMATOLOGY; DISEASES; LIBRARIES; MAMMALS; ONCOLOGY; VIRUSES;

TUMORS;

COMPLEMENTARY DNA; EPITOPE; GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; HLA A ANTIGEN; INTERLEUKIN 17; MELANOCYTE PROTEIN PMEL 17; TRANSFORMING GROWTH FACTOR BETA; TUMOR REJECTION ANTIGEN; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS COMPLEMENTARY DNA;

5' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CLONING; CONTROLLED STUDY; DNA LIBRARY; GENE MUTATION; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOID CELL; MELANOMA; MOUSE; NONHUMAN; PLAQUE FORMING CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; TUMOR SEEDING; VACCINATION; VESICULAR STOMATITIS VIRUS; VIRUS IDENTIFICATION;

ANIMALS; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; GENE LIBRARY; GENETIC VECTORS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; INTERLEUKIN-17; LYMPHOCYTES; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; NEOPLASMS, EXPERIMENTAL; VESICULOVIRUS;

MUS; VESICULAR STOMATITIS VIRUS;

EID: 84859646663     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2157     Document Type: Article

References (43)

1. Pardoll, D.M. Cancer vaccines. Nat. Med. 4, 525-531 (1998).
2. Park, T.S., Rosenberg, S.A. & Morgan, R.A. Treating cancer with genetically engineered T cells. Trends Biotechnol. 29, 550-557 (2011).
3. Uchi, H. et al. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv. Immunol. 90, 215-241 (2006).
4. Koos, D. et al. Tumor vaccines in 2010: need for integration. Cell. Immunol. 263, 138-147 (2010).
5. Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526 (2011).
6. Rosenberg, S.A. & Dudley, M.E. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 21, 233-240 (2009).
7. Drake, C.G., Jaffee, E.M. & Pardoll, D.M. Mechanisms of immune evasion by tumors. Adv. Immunol. 90, 51-81 (2006).
8. Poschke, I., Mougiakakos, D. & Kiessling, R. Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol. Immunother. 60, 1161-1171 (2011).
9. Gogas, H. et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354, 709-718 (2006).
10. Daniels, G. et al. A simple method to cure established tumors by inflammatory killing of normal cells. Nat. Biotechnol. 22, 1125-1132 (2004).
11. Ferrone, S. Immunotherapy dispenses with tumor antigens. Nat. Biotechnol. 22, 1096-1098 (2004).
12. Kottke, T. et al. Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas. Cancer Res. 69, 7767-7774 (2009).
13. Kottke, T. et al. Induction of hsp70-mediated, Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. Cancer Res. 67, 11970-11979 (2007).
14. Sanchez-Perez, L. et al. Killing of normal melanocytes, combined with hsp70 and CD40L expression, cures large established melanomas. J. Immunol. 177, 4168-4177 (2006).
15. Sanchez-Perez, L. et al. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res. 65, 2009-2017 (2005).
16. Turk, M.J., Wolchok, J.D., Guevara-Patino, J.A., Goldberg, S.M. & Houghton, A.N. Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol. Rev. 188, 122-135 (2002).
17. Alvarez-Breckenridge, C. & Chiocca, E.A. A viral strategy to ambush tumors. Nat. Med. 17, 784-785 (2011).
18. Kottke, T. et al. Broad antigenic coverage induced by viral cDNA library-based vaccination cures established tumors. Nat. Med. 17, 854-859 (2011).
19. Braxton, C.L., Puckett, S.H., Mizel, S.B. & Lyles, D.S. Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens. J. Virol. 84, 3552-3561 (2010).
20. Bridle, B.W. et al. Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol. Ther. 17, 1814-1821 (2009).
21. Bridle, B.W. et al. Potentiating cancer immunotherapy using an oncolytic virus. Mol. Ther. 18, 1430-1439 (2010).
22. Cobleigh, M.A., Bouonocore, L., Uprichard, S.L., Rose, J.K. & Robek, M.D. A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose. J. Virol. 84, 7513-7522 (2010).
23. Diaz, R.M. et al. Oncolytic immunovirotherapy for melanoma using Vesicular Stomatitis Virus. Cancer Res. 67, 2840-2848 (2007).
24. Geisbert, T.W. et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J. Virol. 83, 7296-7304 (2009).
25. Qiao, J. et al. Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat. Med. 14, 37-44 (2008).
26. Schwartz, J.A. et al. Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge. J. Virol. 84, 4611-4618 (2010).
27. Guevara-Patino, J.A. et al. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J. Clin. Invest. 116, 1382-1390 (2006).
28. Guevara-Patino, J.A., Turk, M.J., Wolchok, J.D. & Houghton, A.N. Immunity to cancer through immune recognition of altered self: studies with melanoma. Adv. Cancer Res. 90, 157-177 (2003).
29. Overwijk, W.W. et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198, 569-580 (2003).
30. Overwijk, W. et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198, 569-580 (2003).
31. Galivo, F. et al. Interference of CD40L-mediated tumor immunotherapy by oncolytic VSV. Hum. Gene Ther. 21, 439-450 (2010).
32. Galivo, F. et al. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Ther. 17, 158-170 (2010).
33. Wongthida, P. et al. VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling. Mol. Ther. 19, 150-158 (2011).
34. Willmon, C. et al. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intra-tumoral oncolytic virus and cyclophosphamide. Mol. Ther. 19, 140-149 (2011).
35. Hogquist, K.A. et al. T cell receptor antagonistic peptides induce positive selection. Cell 76, 17-27 (1994).
36. Hall, A. & Brown, R. Human N-ras: cDNA cloning and gene structure. Nucleic Acids Res. 13, 5255-5268 (1985).
37. Shibata, K., Takeda, K., Tomita, Y., Tagami, H. & Shibahara, S. Downstream region of the human tyrosinase-related protein gene enhances its promoter activity. Biochem. Biophys. Res. Commun. 184, 568-575 (1992).
38. Suzuki, H., Hosokawa, Y., Nishikimi, M. & Ozawa, T. Structural organization of the human mitochondrial cytochrome c1 gene. J. Biol. Chem. 264, 1368-1374 (1989).
39. Rausch, M.P. et al. GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1. J. Immunol. 185, 2828-2835 (2010).
40. Tanaka, S. et al. Target killing of carcinoembryonic antigen (CEA) - producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein-Barr virus (EBV)-based plasmid vector carrying the CEA promoter. Cancer Gene Ther. 7, 1241-1249 (2000).
41. Thomas, D.A. & Massague, J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369-380 (2005).
42. Linardakis, E. et al. Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res. 62, 5495-5504 (2002).
43. Fernandez, M., Porosnicu, M., Markovic, D. & Barber, G.N. Genetically engineered vesicular stomatitis virus in gene therapy: Application for treatment of malignant disease. J. Virol. 76, 895-904 (2002).